constant
emerg
reemerg
known
novel
pathogen
challeng
research
develop
new
vaccin
technolog
allow
rapid
develop
safe
effect
vaccin
nucleic
acid
dna
rna
vaccin
characterist
meet
challeng
includ
eas
product
scalabl
consist
lot
storag
safeti
dna
vaccin
technolog
usual
base
bacteri
plasmid
encod
polypeptid
sequenc
candid
antigen
encod
antigen
express
strong
eukaryot
promot
yield
high
level
transgen
inclus
transcript
enhanc
intron
enhanc
rate
polyadenyl
nuclear
transport
messeng
rna
mrna
vaccin
plasmid
gener
produc
bacteri
cultur
purifi
use
inocul
host
modern
dna
vaccin
design
gener
reli
synthesi
nucleic
acid
possibl
onestep
clone
plasmid
vector
reduc
cost
time
manufactur
plasmid
dna
also
extrem
stabl
room
temperatur
reduc
need
cold
chain
transport
vaccin
dna
plasmid
remov
necess
protein
purif
infecti
pathogen
improv
safeti
furthermor
dna
vaccin
excel
safeti
profil
clinic
common
side
effect
mild
inflamm
inject
importantli
dna
vaccin
provid
safe
nonliv
vaccin
approach
induc
balanc
immun
respons
vivo
product
antigen
allow
present
class
class
ii
major
histocompat
complex
mhc
molecul
fig
elicit
antigen
specif
well
cytotox
lymphocyt
respons
ctl
someth
remain
elus
nonliv
vaccin
dna
vaccin
also
demonstr
abil
gener
follicular
helper
critic
induct
high
qualiti
antigenspecif
b
cell
dna
vaccin
proven
success
sever
anim
model
prevent
treat
infecti
diseas
allergi
cancer
earli
success
small
anim
studi
led
sever
human
clinic
trial
howev
protect
immun
observ
small
anim
nonhuman
primat
observ
human
studi
dna
vaccin
administ
alon
needl
deliveri
like
convent
proteinbas
vaccin
dna
deliv
varieti
rout
includ
intramuscular
im
intraderm
id
mucos
transderm
deliveri
dna
plasmid
must
enter
host
cell
nuclei
transcrib
mrna
earli
failur
dna
vaccin
elicit
strong
respons
human
larg
due
deliveri
needl
inject
deposit
dna
intracellular
space
rather
within
cell
improv
deliveri
technolog
intramuscular
intraderm
electropor
use
facilit
transport
dna
cell
result
much
better
immunogen
clinic
nonclin
one
studi
electroporationenhanc
dna
vaccin
result
increas
polyfunct
antigenspecif
cell
patient
receiv
hpv
dna
vaccin
express
gene
major
dna
vaccin
patient
display
complet
regress
cervic
lesion
well
viral
clearanc
follow
dna
deliveri
mechan
deliveri
approach
use
physic
forc
particl
bombard
gene
gun
deliv
dna
plasmid
target
tissu
cell
clinic
deliveri
hepat
b
dna
vaccin
particl
bombard
result
sustain
antibodi
titer
subject
previous
fail
respond
licens
subunit
needlefre
pneumat
jet
injector
also
shown
promis
anim
human
clinic
function
inject
highpressur
narrow
stream
inject
liquid
epidermi
muscl
test
subject
addit
improv
mechan
deliveri
method
sever
approach
explor
increas
immunogen
dna
vaccin
human
review
approach
show
promis
advanc
dna
vaccin
nonmechan
deliveri
inclus
molecular
adjuv
improv
dna
vaccin
vector
alreadi
mention
greatest
impedi
dna
vaccin
low
immunogen
due
difficulti
deliv
dna
plasmid
host
cell
transport
dna
vaccin
plasmid
cellular
nuclei
requir
cross
sever
barrier
vaccin
plasmid
must
cross
phospholipid
cellular
membran
endocytosi
pinocytosi
escap
degrad
endosom
lysosom
surviv
cytosol
nucleas
transloc
across
nuclear
envelop
contrast
physic
deliveri
system
chemic
deliveri
approach
use
biopharmaceut
increas
dna
vaccin
transfect
effici
use
liposom
carrier
molecul
becom
popular
dna
vaccin
deliveri
method
liposom
enhanc
transfect
effici
also
adjuv
effect
liposom
spheric
vesicl
compos
phospholipid
cholesterol
arrang
lipid
bilay
allow
fusion
cellular
lipid
dna
plasmid
either
bound
liposom
surfac
encas
within
hydrophob
core
liposom
facilit
deliveri
dna
vaccin
plasmid
cell
importantli
lipid
vesicl
formul
either
unilamellar
multilamellar
multilamellar
vesicl
allow
sustain
deliveri
vaccin
extend
period
time
use
liposom
im
inject
result
reactogen
liposomedna
vaccin
complex
demonstr
immunolog
benefit
im
inject
liposomeinfluenza
nucleoprotein
formul
increas
antibodi
titer
compar
vaccin
boost
antibodi
titer
diminish
cytotox
cell
respons
likewis
inclus
liposom
formul
p
falciparum
vaccin
enhanc
ensu
human
trial
involv
dna
plasmid
encod
influenza
ha
nucleoprotein
gene
report
cellular
immun
respons
rate
antibodi
titer
compar
current
avail
inactiv
proteinbas
addit
liposom
shown
promis
candid
deliveri
dna
vaccin
mucos
recent
studi
demonstr
vaccin
liposom
encapsul
influenza
viru
induc
humor
cellular
immun
respons
protect
respiratori
liposom
also
shown
effect
deliveri
method
intranas
dna
vaccin
confer
protect
immun
respons
dna
vaccin
deliveri
also
accomplish
use
biodegrad
polymer
micro
nanoparticl
consist
amphiphil
molecul
size
similar
load
dna
plasmid
liposom
plasmid
molecul
either
encapsul
adsorb
onto
surfac
particl
function
carrier
system
protect
vaccin
plasmid
degrad
extracellular
deoxyribonucleas
addit
shield
plasmid
dna
nucleas
micro
nanoparticl
promot
sustain
releas
vaccin
instead
bolu
type
deliveri
characterist
larger
submicromet
high
molecular
weight
cation
polym
proven
significantli
effect
cation
liposom
aggreg
dna
vaccin
plasmid
plasmid
dna
immobil
within
biodegrad
chitosanco
polymer
microspher
rang
induc
mucos
system
immun
microspher
may
deliv
either
oral
intraperiton
rout
allow
direct
transfect
dendrit
cell
dc
therebi
increas
dc
activ
benefit
microspher
formul
shown
mice
nonhuman
primat
human
wide
rang
diseas
includ
hepat
result
suggest
microparticlebas
deliveri
system
capabl
significantli
improv
dna
vaccin
immunogen
boost
cellular
humor
immun
respons
use
liposom
nanoparticl
appear
safe
well
toler
clinic
studi
microparticlebas
deliveri
system
increas
gene
express
well
dna
vaccin
immunogen
although
mani
earliest
carrier
formul
show
signific
clinic
benefit
recent
studi
highlight
herein
yield
promis
clinic
data
microparticl
prepar
signific
structur
divers
size
surfac
charg
lipid
content
offer
consider
flexibl
vaccin
formul
allow
optim
vaccin
base
specif
need
clinician
cytokin
class
immunoregulatori
protein
affect
behavior
cell
critic
immun
cell
signal
cytokineencod
gene
deliv
either
separ
plasmid
addit
gene
encod
within
antigen
contain
plasmid
extens
studi
molecular
adjuv
play
essenti
role
immun
respons
promot
differenti
cell
effector
cell
well
drive
gener
memori
cell
pool
also
requir
prolifer
natur
killer
nk
cell
inclus
result
improv
immunogen
antivir
dna
vaccin
interestingli
therapeut
vaccin
encod
bcrablpir
gene
myeloid
leukemia
also
demonstr
enhanc
immun
respons
suggest
molcular
adjuv
capabl
allevi
symptom
chronic
similar
cytokin
induc
nk
cell
prolifer
necessari
gener
primari
antigenspecif
cell
respons
also
play
substanti
role
establish
memori
cell
result
small
anim
studi
suggest
adjuv
effect
potent
deliv
tandem
cytokin
exampl
synergist
effect
seen
codeliv
dna
vaccin
toxoplasma
gondii
addit
sequenti
administr
gene
augment
longterm
cell
memori
respons
foot
mouth
diseas
dna
therefor
depend
antigen
may
necessari
deliv
combin
molecular
adjuv
notabl
studi
rhesu
macaqu
suggest
deliveri
encod
dna
vaccin
result
increas
prolifer
nk
cell
advers
anoth
recent
studi
demonstr
covaccin
rhesu
macaqu
siv
pol
plasmid
hiv
env
plasmid
plu
allow
faster
control
viremia
group
formul
moreov
macaqu
vaccin
exhibit
increas
cell
prolifer
compar
receiv
antigen
plasmid
alon
suggest
robust
effect
cell
memori
respons
anoth
proinflammatori
cytokin
secret
dendrit
cell
monocyt
play
integr
role
shape
innat
adapt
immun
respons
signal
support
secondari
expans
activ
helper
result
high
level
antigenspecif
cell
express
cytotox
mediat
granzym
b
first
cytokin
evalu
use
molecular
adjuv
sever
studi
shown
inclus
express
plasmid
within
vaccin
formul
enhanc
immun
vaccin
mice
bicistron
plasmid
express
yersinia
pesti
result
increas
mucos
iga
serum
igg
provid
significantli
higher
level
protect
challeng
antigenonli
studi
rhesu
macaqu
shown
similar
increas
dna
vaccin
immunogen
covaccin
siv
gag
allow
dose
well
increas
breadth
cell
addit
multipl
human
clinic
studi
use
vaccin
adjuv
proven
highli
immunogen
yield
high
level
cell
furthermor
inclus
express
plasmid
improv
weakli
immunogen
vaccin
recent
clinic
studi
demonstr
addit
improv
immunogen
hepat
b
dna
vaccin
result
increas
vaccin
immunogen
well
sustain
memori
cell
final
immunomodulatori
cytokin
receiv
consider
focu
molecular
adjuv
granulocytemacrophag
coloni
stimul
factor
gmcsf
gmcsf
recruit
antigen
present
cell
vaccin
site
promot
dc
success
use
multipl
dna
plasmidencod
gmcsf
codeliv
rabi
viru
dna
vaccin
mice
result
increas
cell
respons
antibodi
product
protect
lethal
viral
likewis
bicistron
dna
vaccin
encod
gmcsf
recruit
inflammatori
cellular
infiltr
elicit
potent
cell
howev
benefit
gmcsf
molecular
adjuv
remain
unclear
recent
studi
shown
coadministr
gmcsf
plasmid
antigenencod
dna
vaccin
deleteri
effect
codeliveri
gmcsf
suppress
respons
dna
vaccin
encod
dengu
viru
type
type
also
fail
improv
respons
elicit
hepat
c
furthermor
inclus
plasmid
gmcsf
provid
minim
adjuv
effect
coadminist
malaria
dna
vaccin
rhesu
likewis
gmcsf
clear
effect
cell
respons
patient
receiv
melanoma
dna
one
possibl
explan
result
high
level
gmcsf
expand
myeloid
suppressor
cell
popul
suppress
gener
adapt
immun
respons
altern
lack
improv
immunogen
seen
clinic
trial
may
due
rel
lack
gmcsf
receptor
rhesu
human
apc
compar
murin
specif
advers
effect
report
use
gmcsf
adjuv
may
requir
finetun
particularli
gmcsf
express
level
must
consid
regard
immunosuppress
addit
cytokineencod
plasmid
sever
method
increas
dna
vaccin
immunogen
exist
increas
understand
immun
signal
pathway
led
develop
adjuv
plasmid
encod
adhes
molecul
chemokin
costimulatori
molecul
tolllik
receptor
tlr
ligand
molecular
adjuv
success
small
anim
model
exampl
innat
immun
signal
molecul
trif
increas
antibodi
respons
gener
swine
fever
viru
dna
moreov
trif
increas
protect
activ
influenza
haencod
dna
similar
result
seen
studi
encod
dsrna
receptor
addit
antigenfus
construct
wherebi
antigen
interest
link
carrier
protein
increas
immun
visibl
vaccin
enhanc
dna
vaccin
major
advantag
dna
vaccin
abil
multipl
molecul
molecular
adjuv
insert
plasmid
unlik
addit
recombin
cytokin
costimulatori
molecul
tlr
ligand
limit
durat
due
short
halflif
recombin
protein
vivo
molecular
adjuvantencod
plasmid
express
protein
durat
antigen
stimul
immun
system
greater
length
time
done
without
fear
elicit
cytokin
storm
gener
adjuv
signal
local
site
vaccin
note
homolog
recombin
plasmidencod
cytokin
host
gene
sequenc
appear
signific
concern
multipl
studi
shown
extrachromosom
plasmid
dna
identifi
follow
intramuscular
furthermor
mani
current
plasmid
beencodon
optim
improv
gene
express
mammalian
cell
result
chang
cytokin
gene
sequenc
limit
possibl
homolog
recombin
andor
integr
molecular
adjuv
therefor
show
great
promis
increas
immunogen
extend
longev
immun
respons
plasmid
dna
vector
contain
function
element
origin
replic
select
marker
requir
prokaryot
growth
process
e
coli
bacteri
region
element
fig
longer
need
cell
cultur
halt
may
neg
effect
vaccin
stabil
uptak
efficaci
addit
element
pose
safeti
concern
particularli
wide
use
antibiot
resist
marker
horizont
transmit
host
enter
bacteria
concern
address
develop
small
bacteri
rnabas
antibiot
free
select
noncod
rna
marker
prefer
protein
marker
sinc
protein
like
antibiot
resist
marker
express
host
organ
vector
transfect
horizont
transmit
host
bacteria
noncod
rna
marker
also
small
basepair
decreas
overal
vector
size
advantag
sinc
vector
transfect
effici
invers
relat
vector
perhap
smaller
vector
resist
deliveri
associ
shear
may
improv
nuclear
local
sinc
motil
addit
bacteri
region
protein
marker
gene
shown
dramat
reduc
vector
express
exampl
deriv
nptii
kanamycin
resist
marker
kanr
gene
vector
bacteri
region
significantli
reduc
transgen
express
three
group
demonstr
bacteri
region
mediat
repress
transgen
express
allevi
replac
kanr
gene
either
trna
rna
select
marker
rnaout
antisens
rna
select
marker
endogen
puc
origin
rnai
antisens
rna
select
consist
remov
bacteri
region
minicircl
vector
improv
humor
cellular
immun
respons
compar
vector
dna
vaccin
vector
dramat
higher
transgen
express
recent
develop
identif
novel
bacteri
region
eukaryot
region
vector
configur
pioneer
work
mark
kay
laboratori
stanford
univers
demonstr
bacteri
region
larger
kbase
silenc
transgen
express
quiescent
tissu
liver
like
due
untranscrib
bacteri
region
mediat
heterochromatin
format
spread
eukaryot
region
inactiv
minicircl
vector
bacteri
region
remov
action
phage
recombinas
product
allevi
howev
product
minicircl
vector
low
yield
poorli
scalabl
due
requir
vivo
vitro
recombin
effort
creat
altern
short
bacteri
region
vector
could
effici
manufactur
miniintron
plasmid
mip
vector
plasmid
platform
develop
mip
vector
incorpor
rnaout
select
markerpuc
origin
bacteri
region
within
utr
intron
configur
bacteri
region
within
transcript
unit
downstream
polya
signal
link
eukaryot
promot
without
interven
select
marker
replic
origin
vector
rnaout
select
marker
vector
larg
puc
bacteri
replic
origin
replac
small
bacteri
replic
origin
configur
basepair
bp
bacteri
region
separ
polya
signal
eukaryot
promot
unlik
minicircl
mip
rnaout
select
vector
effici
manufactur
gramlit
yield
without
antibiot
expect
vector
platform
allevi
gene
silenc
quiescent
tissu
similarli
minicircl
howev
unexpectedli
mip
vector
dramat
improv
overal
gene
express
compar
plasmid
minicircl
vector
quiescent
liver
nonquiesc
improv
express
level
id
im
deliveri
applic
improv
dna
vaccin
sinc
increas
express
level
correl
improv
humor
cellular
immun
anoth
approach
improv
dna
vaccin
engin
vector
increas
innat
immun
activ
dna
vaccin
potent
trigger
innat
immun
variou
studi
determin
sever
innat
immun
pathway
activ
dna
vaccin
fig
intrins
adjuv
effect
dna
mediat
cytoplasm
innat
immun
receptor
nonspecif
recogn
b
dna
activ
sting
inflammasom
mediat
unmethyl
cpg
sequenc
specif
activ
may
also
import
prime
cell
along
line
dna
vaccin
vector
may
sequenc
modifi
introduc
immunostimulatori
xxcgxx
agonist
vector
increas
innat
immun
activ
approach
use
improv
dna
vaccin
result
variabl
variabl
may
due
unintend
inhibit
eukaryot
promot
express
result
integr
cpg
motif
nonpermiss
site
well
certain
dna
deliveri
method
may
transfer
dna
endosom
effect
deliveri
eg
liposom
prevent
unmethyl
cpg
interact
activ
part
complex
optim
activ
xxcgxx
motif
speciesspecif
differ
xxcgxx
agonist
motif
differenti
modul
immun
mani
xxcgxx
motif
immunosuppress
altern
strategi
encod
immunostimulatori
rna
within
plasmid
increas
innat
immun
activ
approach
potenti
advantag
addit
innat
immun
pathway
normal
stimul
dna
alon
activ
result
polyval
activ
multipl
innat
immun
pathway
enhanc
immun
like
dna
sever
innat
immun
tlr
rna
activ
receptor
requir
motif
introduct
express
rna
well
cytoplasm
rna
shuttl
endosom
autophagi
exampl
incorpor
bp
immunostimulatori
ssrna
encod
type
cpg
upstream
bp
hairpin
dsrna
result
increas
antigen
reactiv
igg
increas
secret
moreov
sever
rnasens
innat
immun
receptor
rigi
dna
vaccin
express
rna
use
target
receptor
directli
without
autophagi
rigi
particular
interest
sinc
rigi
agonist
demonstr
adjuv
properti
improv
humor
humor
cell
cell
coadminist
addit
rigi
ubiquiti
express
tissu
express
tlr
typic
restrict
immun
cell
subtyp
certain
rigi
agonist
express
dna
vaccin
eg
blunt
dsrna
triphosph
structur
conserv
human
mice
dna
vaccin
vector
coexpress
antigen
rigi
dsrna
agonist
vector
backbon
encod
rna
polymeras
iii
transcript
unit
fig
enhanc
humor
cell
respons
dna
dna
vaccin
encod
immunostimulatori
sequenc
select
improv
ctl
respons
encod
antigen
may
nich
applic
vaccin
intracellular
pathogen
cancer
innov
increas
transgen
express
may
use
improv
perform
immunomodulatori
molecular
adjuv
plasmid
addit
tradit
antigen
express
dna
vaccin
plasmid
collect
vector
design
innov
improv
transgen
express
level
innat
immun
activ
complementari
improv
mechan
nonmechan
dna
vaccin
deliveri
platform
combin
improv
vector
liposom
polymer
particl
nonmechan
deliveri
needl
free
injector
devic
deliveri
potenti
increas
immunogen
well
toler
safe
deliveri
platform
dna
vaccin
provid
sever
advantag
convent
vaccin
strategi
optim
necessari
becom
predomin
strategi
human
patient
despit
initi
setback
signific
progress
made
overcom
problem
low
immunogen
human
clearer
understand
immun
mechan
govern
dna
vaccin
immunogen
illumin
sever
pathway
may
use
improv
dna
vaccin
efficaci
larg
catalog
cytokin
chemokin
adhes
molecul
transcript
factor
process
test
molecular
adjuv
although
like
need
care
assess
safeti
toler
likewis
continu
develop
vaccin
deliveri
method
appear
promis
new
formul
exploit
sustain
vaccin
deliveri
method
slowreleas
micropatch
multilamellar
vesicl
horizon
strong
appeal
needlefre
inject
mucos
deliveri
eas
design
recent
clinic
success
dna
vaccin
suggest
approach
precipic
redefin
field
vaccinolog
